MedTrace Logo

Dose Effects of Hormone Therapy (Two Doses of Estradiol Associated to Progesterone) on Inflammatory Markers

NCT00236301 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2008-01-17

No results posted yet for this study

Summary

Primary purpose : Effects of two doses of hormone therapy on hsCRP. The effects of hormone replacement therapy on inflammatory markers are dose-dependent.

Conditions

  • Healthy Symptomatic Menopausal Women

Interventions

DRUG

CLIMASTON (drug)

CLIMASTON(drug)

DRUG

17 Beta-estradiol (2mg/day)and (1mg/day)

17 Beta-estradiol (2mg/day)and (1mg/day)

DRUG

placebo

placebo

Sponsors & Collaborators

  • French Health Products Safety Agency

    collaborator OTHER_GOV

  • FRM

    collaborator UNKNOWN

  • Solvay Pharmaceuticals

    collaborator INDUSTRY

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Tabassome Simon, M.D., Ph.D. · Service de Pharmacologie (Pr Jaillon) CHU Saint-Antoine 27, rue de Chaligny, 75012 Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2006-06-30
Completion
2007-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00236301 on ClinicalTrials.gov